Skip to main content
| News

ACROBiosystems establishes presence in the Basel Area

21.02.2022

ACROBiosystems AG, who operates in the US and in Asia, has selected the Basel Area for its first European location. From here, the biopharmaceutical firm headquartered in Beijing plans to expand its research and commercial activities in Europe.

ACROBiosystems about the Basel Area

ACROBiosystems, which is headquartered in Beijing, is to establish a presence at the Allschwil site of the Switzerland Innovation Park Basel Area. This is the biopharmaceutical firm’s first European subsidiary, while it already operates a site in Newark in the US State of Delaware (read more about starting a business in Switzerland). From the Basel Area, ACROBiosystems intends to expand its research and commercial activities across Europe, according to a statement. Both, the investment and innovation promotion agency Basel Area Business & Innovation and the foundation Switzerland Innovation, which brings innovative companies into contact with scientific institutions, supported ACROBiosystems in establishing its business in the area. “We welcome ACROBiosystems as promising contributor to our vibrant life sciences community at the Switzerland Innovation Park Basel Area in Allschwil”, comments Karin Crisanto, Head Innovation Space and Infrastructure at Basel Area Business & Innovation. “With its focus on collaboration with local customers and partners the company is a good fit for us.”

Basel Area as a valuable base

ACROBiosystems manufactures proteins, antibodies and other reagents for biopharmaceutical research. According to information from the company itself, by opening a new subsidiary, the aim is “to accelerate the growth of the company with our first active presence in Europe. The company supports academic and industrial clients working on target therapeutics, vaccines and diagnostics in all phases of product development.” As CEO Mike Chen explains, ACROBiosystems is keen to “foster better relationships with renowned universities, research institutions and hospitals in Switzerland” with the ultimate aim of supporting “new product development to better understand and serve the biomedical field”.

The new location in the Basel Area is “exciting for us as it offers a valuable base for sales and marketing, better geographic coverage of our customers and collaborators and provides a foundation for our future plans of developing a facility for manufacturing, research and development to grow from”. Chen explains further in the statement.

Learn what it’s like to work in Switzerland, what permits you need as a foreign worker and how to find work here. Check out our working in Switzerland page for more info.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.